{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-003052","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.510104+00:00","generated_at":"2026-06-19T17:21:47.994306+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Integrated BioPharma Q2 revenue falls 15.6% YoY; swings to net loss of $55K","bullets":["Revenue $12.3M vs $14.6M a year ago; operating loss ~$33K vs income $0.7M.","Net loss of $55K ($0.00 per share) vs net income $1.0M ($0.04) in prior-year quarter.","Six-month revenue $24.6M (-9.9% YoY); net loss $90K vs income $1.5M.","Co-CEOs cite customer overstocking during pandemic as primary cause of sales decline.","Two largest customers in Contract Manufacturing Segment represent ~91% of total revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-003052","json":"https://secwatch.observer/filing/0001437749-23-003052.json","markdown":"https://secwatch.observer/filing/0001437749-23-003052.md","text":"https://secwatch.observer/filing/0001437749-23-003052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/0001437749-23-003052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/inbp20230209_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T17:21:47.994306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"979db8dcd525d2069cb1461800735092628506c6","claim":"INTEGRATED BIOPHARMA INC reported the six-month period ended December 31, 2022 results: revenue $24.6 million, net income approximately $90,000, EPS $0.00 per share of common stock.","evidence_excerpt":"31, 2022 of approximately $33,000 and operating income of $0.7 million for the quarter ended December 31, 2021. Revenue for the six-month period ended December 31, 2022 was $24.6 million compared to $27.3 million for the six-month period ended December 31, 2021, a decrease of $2.7 million or 9.9%. The Company had an operating loss for the six-month period ended","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/0001437749-23-003052-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six-month period ended December 31, 2022"},{"label":"Revenue","value":"$24.6 million"},{"label":"Net income","value":"approximately $90,000"},{"label":"EPS","value":"$0.00 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"de9e71fcda0573883f43380cfa1ce20784d0a124","claim":"INTEGRATED BIOPHARMA INC reported the quarter ended December 31, 2022 results: revenue $12.3 million, net income approximately $55,000, EPS $0.00 per share of common stock.","evidence_excerpt":"Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended December 31, 2022. Revenue for the quarter ended December 31, 2022 was $12.3 million compared to $14.6 million for the quarter ended December 31, 2021, a decrease of $2.3 million or 15.6%. The Company had an operating loss for the quarter ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1016504/000143774923003052/0001437749-23-003052-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$12.3 million"},{"label":"Net income","value":"approximately $55,000"},{"label":"EPS","value":"$0.00 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}